 |
[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide |
|---|---|
| Trade Name | |
| Orphan Indication | Metastatic melanoma, stages IIB, IIC, III and IV |
| USA Market Approval | USA |
| USA Designation Date | 2008-09-17 00:00:00 |
| Sponsor | Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary);777 Old Saw Mill River Road;Tarrytown, New York, 10591 |
